CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Parnell Pharmaceuticals Holdings Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Parnell Pharmaceuticals Holdings Ltd
Unit 4 476 Gardeners Road
Phone: +61 296674411p:+61 296674411 ALEXANDRIA, NSW  2015  Australia Ticker: PARNFPARNF

This company was Merged or Acquired on 3/2/2021.
This company ceased filing statements with the SEC on 1/3/2017.
This is a Subsidiary, click here for the Parent Company

Business Summary
Parnell Pharmaceuticals Holdings Ltd is an Australia-based fully integrated, commercial-stage pharmaceutical company. The Company is focused on developing, manufacturing and marketing animal health solutions. It markets products for companion, performance and production animals enhanced with software platforms designed to improve compliance and clinical outcomes. It markets cattle breeding programs as well as osteoarthritis solutions for dogs and horses. The Company's companion animal products include GLYDE Mobility Chews and ZYDAX Injection. Its reproduction product portfolio includes GONAbreed, estroPLAN and Parnell PROcept. Its performance products include ZYDAX and GLYDE. GLYDE Mobility Chews offer a solution that controls the clinical signs of arthritis in dogs, and aids in improvement of joint health and function. The Company is also focused on developing mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201612/31/2015YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board AlanBell 60 1/1/2006 1/1/2006
President, Chief Executive Officer, Director RobertJoseph 40 8/1/2006 8/1/2006
Chief Financial Officer, Director BradMccarthy 41 2/1/2010 2/1/2010
Independent Director Anthony G.Hartnell 71 1/4/2018 1/4/2018

Business Names
Business Name
58P
PARN
PARNF

General Information
Number of Employees: 51 (As of 6/30/2014)
Outstanding Shares: 18,023,814 (As of 3/31/2019)
Stock Exchange: OTC


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, August 29, 2023